| Page 39 | Kisaco Research

Explore how AI accelerates antibody discovery by enabling de novo design, epitope prediction, and in silico affinity maturation for highly specific, developable therapeutics.
Learn how deep learning and structure-based models optimize antibody stability, immunogenicity and target binding to advance precision biologics.

Author:

Adam Root

Vice President & Head, Protein Sciences
Generate Biomedicines

Adam Root

Vice President & Head, Protein Sciences
Generate Biomedicines

Author:

Claudette Fuller

Vice President, Non Clinical Safety & Toxicology
Genmab

Claudette Fuller

Vice President, Non Clinical Safety & Toxicology
Genmab

Showcasing generative models that craft hyper‑personalized outreach messages and informed consent materials, driving up engagement rates and shaving weeks off recruitment timelines.
Discover how ML‑driven forecasts for recruitment rates and optimized site selection translate into faster first‑patient‑in and lower screen‑fail/dropout rates, saving you both time and budget.

Author:

Claire Zhao

Associate Director, AI/ML & Quantitative & Digital Sciences
PFIZER

Claire Zhao

Associate Director, AI/ML & Quantitative & Digital Sciences
PFIZER

Learn how AI models enhance physics-based simulations to predict molecular interactions and optimize drug design.
Discover the synergy between machine learning and classical methods to accelerate screening and improve the accuracy of drug discovery.

Author:

Sreyoshi Sur

Former Scientist, Molecular Engineering & Modeling
Moderna

Sreyoshi Sur

Former Scientist, Molecular Engineering & Modeling
Moderna

Explore how AI enhances biomarker discovery by analyzing large datasets to uncover novel biomarkers for disease diagnosis and therapeutic efficacy.
Learn how integrating digital biomarkers with AI improves the interpretation of data from wearable devices and traditional lab-based biomarkers for better patient stratification and treatment personalization.

Author:

Satarupa Mukherjee

R&D Leader, AI/ML (Digital Pathology)
Roche

Satarupa Mukherjee

R&D Leader, AI/ML (Digital Pathology)
Roche

Author:

Jack Geremia

CEO
Matterworks

Jack Geremia

CEO
Matterworks

Author:

Virginia Savova

Senior Director, Head Cell-Targeted Precision Medicine
AstraZeneca

Virginia Savova

Senior Director, Head Cell-Targeted Precision Medicine
AstraZeneca

Examine how AI models are being developed, validated, and governed to meet regulatory expectations, with practical insights into documentation, auditability, and lifecycle management to ensure safe, transparent, and compliant deployment in GxP environments.

Explore h ow AI models predict protein 3D structures from sequences, enabling insights into folding pathways and functional conformations
Examine emerging co-folding models that reveal protein–protein interactions and guide multimeric complex design.

Author:

Miles Congreve

Chief Scientific Officer
Isomorphic Labs

Miles Congreve

Chief Scientific Officer
Isomorphic Labs